<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: The fecal immunochemical test (FIT) can identify patients with advanced colorectal <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, but it also has a high rate of false-negative results </plain></SENT>
<SENT sid="1" pm="."><plain>It would be helpful to characterize colorectal <z:hpo ids='HP_0002664'>neoplasms</z:hpo> that are not detected by FIT, to aid in development of new tests </plain></SENT>
<SENT sid="2" pm="."><plain>We characterized colorectal <z:hpo ids='HP_0002664'>neoplasms</z:hpo> from patients who had negative results from the FIT </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We analyzed data from 18,296 subjects who were screened for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> by colonoscopy and the FIT at the Health Management Center of National Taiwan University Hospital from September 2005 through September 2010 </plain></SENT>
<SENT sid="4" pm="."><plain>We identified 4045 subjects with colorectal <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (3385 with non-advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath>, 632 with advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath>, and 28 with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>We analyzed the sensitivity of the FIT in identifying these patients, along with information on lesion size, location, and <z:mp ids='MP_0000002'>morphology</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The FIT identified patients with non-advanced <z:mpath ids='MPATH_270'>adenoma</z:mpath>, advanced <z:mpath ids='MPATH_270'>adenoma</z:mpath>, and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> with sensitivity values of 10.6% (95% confidence interval [CI], 10.2%-12.3%), 28.0% (95% CI, 24.6%-31.7%), and 78.6% (95% CI, 58.5%-91.0%), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>The FIT detected proximal advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath> and nonpolyploid lesions with lower levels of sensitivity than distal advanced <z:mpath ids='MPATH_270'>adenomas</z:mpath>; it had a high false-negative rate in detection of <z:mpath ids='MPATH_270'>adenomas</z:mpath> &lt;15 mm (adjusted odds ratio [aOR], 2.72; 95% CI, 1.76-4.20) and nonpolypoid <z:mpath ids='MPATH_270'>adenomas</z:mpath> (aOR, 2.15; 95% CI, 1.22-3.80), after adjusting for demographic characteristics, colonoscopy findings, and potential confounders </plain></SENT>
<SENT sid="8" pm="."><plain>The FIT had produced a higher percentage false-negative results in detection of <z:mp ids='MP_0002038'>carcinoma</z:mp> in situ and T1 <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> than T2-T4 <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (66.7% sensitivity vs. 100%;P =.049) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The FIT produces a high rate of false-negative results for patients with small or nonpolypoid <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
<SENT sid="10" pm="."><plain>Early-stage of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> are associated with a high rate of false-negative results from the FIT </plain></SENT>
</text></document>